Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial

NCT04785365 is registered in ClinicalTrials.gov with Achilles Therapeutics UK Limited as lead sponsor.

NCT NCT04785365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial
Lead sponsor
Achilles Therapeutics UK Limited
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2022
Completion date
October 18, 2023
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer, melanoma